---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-002808"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T13:39:38.413087+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kintara Q2 net loss $3.5M; cash $4.9M; VAL-083 gets orphan status for DIPG

## Summary
- Net loss of $3.5M vs $5.9M YoY; diluted EPS -$2.10 vs -$6.07.
- Cash and equivalents $4.9M at Dec 31, 2022, down from $11.8M at June 30.
- FDA granted Orphan Drug Designation for VAL-083 in DIPG; Fast Track for REM-001 in CMBC.
- REM-001 program paused to conserve cash, expected savings of ~$3.0M through CY2023.
- Regained Nasdaq minimum bid price compliance after 1-for-50 reverse stock split.

## SEC filing metadata
- accession: 0000950170-23-002808
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017023002808/0000950170-23-002808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017023002808/ktra-20230214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-002808
- JSON: https://secwatch.observer/filing/0000950170-23-002808.json
- Plain text: https://secwatch.observer/filing/0000950170-23-002808.txt

## Key facts
- Earnings Releases
  TuHURA Biosciences, Inc./NV reported fiscal year 2023 second quarter ended December 31, 2022 results: net income net loss of approximately $3.5 million, or $2.10 per share, EPS $2.10 per share.
  - Period: fiscal year 2023 second quarter ended December 31, 2022
  - Net income: net loss of approximately $3.5 million, or $2.10 per share
  - EPS: $2.10 per share
  - Result: reported results
  source text: For the three months ended December 31, 2022, Kintara reported a net loss of approximately $3.5 million, or $2.10 per share, compared to a net loss of approximately $5.9 million, or $6.07 per share, for the three months ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017023002808/0000950170-23-002808-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.